The financing round was led by Kibo Ventures to fund the global rollout of the firm's home sleep testing technology.
"The response to AcuPebble SA100 since its launch has been incredible, and we are thrilled to see the product being used to help patients and clinicians in the real world. This funding will help us reach our initial goal of diagnosing one million patients and gives us the opportunity to continue working on new products that will fundamentally improve the lives of millions of people living with severe chronic conditions."
General Catalyst led the Series A round to support the development of virtual ward infrastructure.
"I’m very proud of our team in completing this successful financing round, marking a significant step in Doccla’s vision of making virtual wards a core part of modern healthcare systems. From the company’s beginnings in 2019, we have continued to grow and expand and have received contract extensions from all of our clients, proving the inherent value of Doccla to the healthcare sector. Combining new technology with a service layer and clinical capacity reduces work for the NHS. We look forward to using this new level of support to further build on our success by getting more hospitals on board and developing our technology and clinical capacity to help solve the hospital bed crisis and alleviate the immense pressures on the NHS and other healthcare systems."
The investment package includes £200k from Finance Yorkshire alongside contributions from the University of Hull and private investors.
"This investment will take MediMusic to the next level. We passionately believe this will be a real game-changer in how we treat dementia patients and people suffering from pain, anxiety and stress."
The Oxford medical technology company secured backing from investors including Mercia and IQ Capital to scale its diagnostic software.
"Following years of research and clinical trials that have shown the impact of our software on the diagnosis of at-risk lung nodules, we’re focused on expanding patient access to this crucial technology and identifying deadly lung cancer faster in more at-risk people. The funding will also boost our research and development with world-leading institutions and partners to progress further innovation."
